Dizal (Jiangsu) Pharmaceutical Co., Ltd. (SHA:688192)

China · Delayed Price · Currency is CNY

37.96

+1.36 (3.72%)

At close: Jun 18, 2026

-37.35% (1Y)

Market Cap	17.66B -31.1%
Revenue (ttm)	894.02M +104.0%
Net Income	-667.09M
EPS	-1.46
Shares Out	465.17M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,068,258
Open	36.58
Previous Close	36.60
Day's Range	35.95 - 38.96
52-Week Range	35.95 - 86.18
Beta	-0.01
Analysts	Strong Buy
Price Target	91.38 (+140.73%)
Earnings Date	Aug 28, 2026

About SHA:688192

Dizal (Jiangsu) Pharmaceutical Co., Ltd., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of oncology and hematologic disorders. Its assets include the ZEGFROVY, for the treatment of solid tumors; Gao Ruizhe to treat hematological malignancy, solid tumors, and immunological diseases; Birelentinib indicated for hematological malignancy; DZD2269, DZD1516, and DZD6008 for solid tumors; and GW5282 for hematological malignancy and solid tumors. Dizal (Jiangsu) Pharmaceutical Co., L... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2017

Employees 1,009

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688192

Full Company Profile

Financial Performance

In 2025, SHA:688192's revenue was 801.14 million, an increase of 122.60% compared to the previous year's 359.90 million. Losses were -764.05 million, -9.68% less than in 2024.

Financial Statements

Analyst Summary

According to 4 analysts, the average rating for 688192 stock is "Strong Buy." The 12-month stock price target is ¥91.38, which is an increase of 140.73% from the latest price.

Price Target

¥91.38

(140.73% upside)

Analyst Consensus: Strong Buy

Stock Forecasts